Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Leow, Yong-Wen | - |
dc.contributor.author | Chan, Wah-Kheong | - |
dc.contributor.author | Goh, George Boon-Bee | - |
dc.contributor.author | Wong, Vincent Wai-Sun | - |
dc.contributor.author | Fan, Jian Gao | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Seung Up | - |
dc.contributor.author | Nakajima, Atsushi | - |
dc.contributor.author | Seto, Wai-Kay | - |
dc.contributor.author | Lee, I-Cheng | - |
dc.contributor.author | Huang, Yi-Hsiang | - |
dc.contributor.author | Kim, Yoon Jun | - |
dc.contributor.author | Young, Jang Jae | - |
dc.contributor.author | Chow, Wan Cheng | - |
dc.date.accessioned | 2023-04-25T02:40:13Z | - |
dc.date.available | 2023-04-25T02:40:13Z | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.issn | 1365-2893 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/22235 | - |
dc.description.abstract | We aimed to compare the severity of liver disease, metabolic profile and cardiovascular disease (CVD) risk of chronic hepatitis B (CHB) patients with and without hepatic steatosis and patients with non-alcoholic fatty liver disease (NAFLD). Patients with NAFLD and CHB were prospectively enrolled from 10 Asian centres. Fibroscan was performed for all patients and hepatic steatosis was defined based on controlled attenuation parameter >248 dB/m. CVD risk was assessed using the Framingham risk score. The data for 1080 patients were analysed (67% NAFLD, 33% CHB). A high proportion (59%) of CHB patients had hepatic steatosis. There was a significant stepwise increase in alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, controlled attenuation parameter and liver stiffness measurement, from CHB patients without hepatic steatosis to CHB patients with hepatic steatosis to NAFLD patients (p < 0.001 for all comparisons). There was a significant stepwise increase in the proportion of patients with metabolic syndrome and in CVD risk, with very high or extreme CVD risk seen in 20%, 48% and 61%, across the groups (p < 0.001 between CHB patients with and without hepatic steatosis and p < 0.05 between CHB patients with hepatic steatosis and NAFLD patients). In conclusion, there was a high proportion of CHB patients with hepatic steatosis, which should be diagnosed, as they may have more severe liver disease, so that this and their metabolic risk factors can be assessed and managed accordingly for a better long-term outcome | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Blackwell Publishing Inc. | - |
dc.title | Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jvh.13796 | - |
dc.identifier.scopusid | 2-s2.0-85146318164 | - |
dc.identifier.wosid | 000911514200001 | - |
dc.identifier.bibliographicCitation | Journal of Viral Hepatitis, v.30, no.4, pp 319 - 326 | - |
dc.citation.title | Journal of Viral Hepatitis | - |
dc.citation.volume | 30 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 319 | - |
dc.citation.endPage | 326 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | FATTY LIVER | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | FIBROSIS | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | CARE | - |
dc.subject.keywordPlus | EPIDEMIOLOGY | - |
dc.subject.keywordPlus | HYPERTENSION | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordAuthor | HBV | - |
dc.subject.keywordAuthor | cardiovascular disease | - |
dc.subject.keywordAuthor | Framingham risk score | - |
dc.subject.keywordAuthor | MAFLD | - |
dc.subject.keywordAuthor | NAFLD | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.